Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovating treatments. The company’s lead pipeline candidate, edasalonexent, is being developed for treating Duchenne muscular dystrophy (“DMD”) in a late-stage study.
Catabasis’ earnings track record has been mixed so far. Over the four trailing quarters, the company posted an average positive earnings surprise of 18.11%, beating estimates in three quarters and missing the same once.
Currently, Catabasis has a Zacks Rank #2 (Buy) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Catabasis reported a loss of 85 cents per share which was narrower than the Zacks Consensus Estimate of loss of 93 cents.
No Revenues: Catabasis recorded no revenues in the quarter. However, revenues in the year-ago quarter were $0.25 million.
Key Stats: General and administrative expenses were up 41% at $2.4 million while research & development expenses decreased 7.5% to $3.7 million. The company ended 2018 with $37.6 million cash, cash equivalents and short-term investments. In February 2019, the company recorded net proceeds of $18.5 million from sale of its common stock.
Share Price Impact:Shares were up 2% in pre-market trading.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovating treatments. The company’s lead pipeline candidate, edasalonexent, is being developed for treating Duchenne muscular dystrophy (“DMD”) in a late-stage study.
Catabasis’ earnings track record has been mixed so far. Over the four trailing quarters, the company posted an average positive earnings surprise of 18.11%, beating estimates in three quarters and missing the same once.
Currently, Catabasis has a Zacks Rank #2 (Buy) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Catabasis reported a loss of 85 cents per share which was narrower than the Zacks Consensus Estimate of loss of 93 cents.
No Revenues: Catabasis recorded no revenues in the quarter. However, revenues in the year-ago quarter were $0.25 million.
Key Stats: General and administrative expenses were up 41% at $2.4 million while research & development expenses decreased 7.5% to $3.7 million. The company ended 2018 with $37.6 million cash, cash equivalents and short-term investments. In February 2019, the company recorded net proceeds of $18.5 million from sale of its common stock.
Share Price Impact:Shares were up 2% in pre-market trading.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>